Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man
Y. A. Kesaniemi and S. M. Grundy
Mechanisms for the hypolipidemic action of gemfibrozil were examined in
seven patients with hypertriglyceridemia. In addition, seven hyperlipidemic
patients were studied with and without clofibrate treatment to compare the
mechanisms by which these two drugs lower plasma triglyceride levels. All
patients were studied on a metabolic ward. The first month was a control
period, followed by one month of either gemfibrozil or clofibrate therapy.
During treatment with gemfibrozil, plasma total triglyceride levels
decreased by an average of 51%, and triglyceride levels in very low-density
lipoproteins (VLDLs) fell by 57%. Transport rates of VLDL triglyceride were
determined by multicompartmental analysis following injection of tritiated
glycerol as a precursor. Gemfibrozil decreased transport (production) of
VLDL triglyceride by an average of 28% and increased the fractional
catabolic rate (FCR) of VLDL triglyceride by 92%. Clofibrate reduced plasma
total triglyceride values on an average of 32% and VLDL triglyceride values
by 38%. In contrast to gemfibrozil, clofibrate did not change transport
rates of VLDL triglyceride but increased the fractional catabolic rate of
VLDL triglyceride by 35%. Gemfibrozil thus decreased production of VLDL
triglyceride and enhanced its clearance, while clofibrate only increased
clearance of VLDL triglyceride. On the average, plasma cholesterol levels
did not fall during gemfibrozil treatment, but levels of cholesterol in
high-density lipoproteins and in low-density lipoproteins increased by 31%
and 11%, respectively. The drug produced a 30% increase in fecal excretion
of neutral steroids and a 37% decrease in fecal excretion of bile acids.
Outputs of total neutral steroids and net cholesterol balance thus remained
unchanged.
Peroxisome proliferator-activated receptor {alpha} polymorphisms and postprandial lipemia in healthy men
Tanaka et al.
J. Lipid Res. 2007;48:1402-1408.
ABSTRACT
| FULL TEXT
PPAR{alpha} activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes
Edvardsson et al.
J. Lipid Res. 2006;47:329-340.
ABSTRACT
| FULL TEXT
Differential regulation of cytosolic and peroxisomal bile acid amidation by PPAR{alpha} activation favors the formation of unconjugated bile acids
Solaas et al.
J. Lipid Res. 2004;45:1051-1060.
ABSTRACT
| FULL TEXT
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
Bilz et al.
J. Lipid Res. 2004;45:174-185.
ABSTRACT
| FULL TEXT
PPAR{alpha} deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins
Linden et al.
J. Lipid Res. 2001;42:1831-1840.
ABSTRACT
| FULL TEXT
Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator-Activated Receptor-{alpha}-Mediated Downregulation of Cholesterol 7{alpha}-Hydroxylase and Sterol 27-Hydroxylase Expression
Post et al.
Arterioscler. Thromb. Vasc. Bio. 2001;21:1840-1845.
ABSTRACT
| FULL TEXT
The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia
Santos et al.
Cardiovasc Res 2001;49:456-465.
ABSTRACT
| FULL TEXT
Long-term Treatment With Pravastatin Alone and in Combination With Gemfibrozil in Familial Type IIB Hyperlipoproteinemia or Combined Hyperlipidemia
Napoli et al.
J CARDIOVASC PHARMACOL THER 1997;2:17-26.
ABSTRACT
Effects of Different Phenotypes of Hyperlipoproteinemia and of Treatment With Fibric Acid Derivatives on the Rates of Cholesterol 7{alpha}-Hydroxylation in Humans
Bertolotti et al.
Arterioscler. Thromb. Vasc. Bio. 1995;15:1064-1069.
ABSTRACT
| FULL TEXT
Reducing Hypertriglyceridemia in Elderly Patients with Cerebrovascular Disease Stabilizes or Improves Cognition and Cerebral Perfusion
Rogers et al.
ANGIOLOGY 1989;40:260-269.
ABSTRACT
The Peroxisome Proliferator-activated Receptor alpha (PPARalpha ) Regulates Bile Acid Biosynthesis
Hunt et al.
J. Biol. Chem. 2000;275:28947-28953.
ABSTRACT
| FULL TEXT